SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh conflicting signals between reports of potential product delays and the company's firm rebuttal that its AI infrastructure roadmap remains intact. Market sentiment is heavily divided, with some community members frustrated by the stock's recent volatility and alleged price manipulation, while others maintain conviction in the long-term fundamentals of the AI compute cycle.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is generating significant community attention following an upbeat revenue forecast and an upward revision to its annual delivery guidance, which has fueled a debate over whether these positive operational updates justify recent share dilution or if the stock remains a high-volatility trading vehicle. Investors are heavily focused on the company's scaling potential and the upcoming R2 launch, while discussions remain polarized between long-term bulls betting on a fundamental turnaround and skeptical traders concerned about the repeated pattern of capital raises capping rally momentum.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently trending due to positive Phase 3 trial data for its COMP360 therapy, which demonstrates durable therapeutic benefits and a strong safety profile. Investors are actively discussing the company's regulatory momentum following FDA support for a rolling NDA submission, while clinical milestone catalysts and potential for breakthrough treatment in depression continue to drive community enthusiasm.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing heightened investor interest driven by a significant price target hike from Goldman Sachs and strategic partnerships, including new collaborations in autonomous driving. While the broader semiconductor sector remains volatile due to concerns over AI-cycle sustainability, the community remains actively divided between bullish sentiment regarding the company's data center and AI compute roadmap and bearish concerns about stretched valuations.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a transformative deal with Anthropic, featuring a 20-year data center lease expected to generate significant long-term revenue. While the stock has seen volatile price action, the community is heavily debating the company's shift from a Bitcoin mining focus to a core AI infrastructure provider, with many investors maintaining bullish long-term sentiment despite recent short-term market fluctuations.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors anticipate a major pivotal Phase 3 trial initiation for its NSCLC pipeline, further validating the commercial potential of its Aglatimagene platform. Community discussion is focused on the company's valuation gap, the upcoming BLA submission for its prostate cancer asset, and speculation regarding its long-term potential as a premier acquisition target for major pharmaceutical companies.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as traders debate whether the current semiconductor pullback is a temporary buying opportunity for the AI cycle or the beginning of a deeper trend reversal. The community is sharply divided, with many actively trading the aggressive swings while others warn of technical breakdown and further downside risk.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is experiencing intense market activity following a ten-billion-dollar acquisition agreement by Vertex Pharmaceuticals, a move that provides a significant premium to shareholders. The community is actively celebrating the buyout while discussing the potential for a sector-wide rotation into similar biotech growth plays and debating whether to hold positions or rotate capital.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending as investors focus on its recently secured U.S. patent for edge-native AI autonomy and its strategic inclusion in Department of War exercises like Northern Strike 26-2. Community discussion is heavily centered on the company's SwarmOS and Gremlin-X technology as a potential disruptor in autonomous defense systems, with many participants actively debating its long-term potential as a defense prime versus the impact of ongoing short interest.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened community engagement driven by intense short interest of over 40% and significant call option activity, leading many investors to monitor the stock for a potential squeeze. While some traders are focused on technical resistance levels and recent merger updates as potential catalysts, others remain cautious of the stock's volatility and historical price patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug 

RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?

Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates...

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.

Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.

International Regulatory Momentum Becoming Key Modern Drug Development Driver

NeOnc Technologies Holdings (NASDAQ:NTHI) remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor

Equity

Bearish Sentiment

Track BMY stock price, charts, news and real-time market activity on Stocktwits. Join the BMY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Bristol-Myers Squibb Co stock.

BMY Stock Price Today - Bristol Myers Squibb News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMYBristol-Myers Squibb Co.

Fundamentals

Latest BMY News